EP2968246A4 - Omega-3 pentaenoic acid compositions and methods of use - Google Patents

Omega-3 pentaenoic acid compositions and methods of use

Info

Publication number
EP2968246A4
EP2968246A4 EP13878433.5A EP13878433A EP2968246A4 EP 2968246 A4 EP2968246 A4 EP 2968246A4 EP 13878433 A EP13878433 A EP 13878433A EP 2968246 A4 EP2968246 A4 EP 2968246A4
Authority
EP
European Patent Office
Prior art keywords
omega
methods
acid compositions
pentaenoic acid
pentaenoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13878433.5A
Other languages
German (de)
French (fr)
Other versions
EP2968246A1 (en
Inventor
Abdel Aziz Fawzy
George Bobotas
Roelof Rongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Publication of EP2968246A1 publication Critical patent/EP2968246A1/en
Publication of EP2968246A4 publication Critical patent/EP2968246A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
EP13878433.5A 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use Withdrawn EP2968246A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/075661 WO2014143272A1 (en) 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use

Publications (2)

Publication Number Publication Date
EP2968246A1 EP2968246A1 (en) 2016-01-20
EP2968246A4 true EP2968246A4 (en) 2016-08-03

Family

ID=51537458

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13878433.5A Withdrawn EP2968246A4 (en) 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use
EP14779339.2A Withdrawn EP2986148A2 (en) 2013-03-13 2014-03-12 Compositions comprising docosapentaenoic acid and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14779339.2A Withdrawn EP2986148A2 (en) 2013-03-13 2014-03-12 Compositions comprising docosapentaenoic acid and methods of use

Country Status (4)

Country Link
EP (2) EP2968246A4 (en)
JP (2) JP2016518315A (en)
CA (2) CA2905671A1 (en)
WO (4) WO2014143272A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6750831B2 (en) * 2014-12-15 2020-09-02 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． Treatment of non-alcoholic fatty liver disease
CN106692973A (en) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 Pharmaceutical compositions and applications thereof, and pharmaceutical preparation
CA3023648C (en) * 2016-05-10 2023-11-28 Shenzhen Hightide Biopharmaceutical, Ltd. Pharmaceutical composition of berberine with epa and dha
CN108778284A (en) * 2017-02-09 2018-11-09 S.L.A.制药股份公司 High-purity free fatty eicosapentaenoic acid reduces patients of ulcerative colitis excrement calprotectin levels and prevents clinical recurrence
CN107006809B (en) * 2017-04-11 2020-06-09 江南大学 Vinegar onion product with blood fat reducing effect and preparation method thereof
JP7099821B2 (en) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 PCSK9 inhibitor and food composition for improving cholesterol metabolism

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098311A1 (en) * 2003-05-05 2004-11-18 Denofa As Fish oils with an altered fatty acid profile, method of producing same and their use
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
US7884131B2 (en) * 2004-11-19 2011-02-08 Martek Biosciences, Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
BRPI1007518A2 (en) * 2009-02-10 2018-02-20 Amarin Pharma, Inc. use of ethyl ester eicopentanoic acid for treatment of hypertriglyceridemia
NZ595204A (en) * 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
EP2424521A4 (en) * 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
US8586567B2 (en) * 2009-10-29 2013-11-19 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
WO2013033618A1 (en) * 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014143272A1 *

Also Published As

Publication number Publication date
WO2014143275A1 (en) 2014-09-18
JP2016518315A (en) 2016-06-23
CA2905795A1 (en) 2014-10-09
EP2986148A2 (en) 2016-02-24
EP2968246A1 (en) 2016-01-20
WO2014143272A1 (en) 2014-09-18
JP2016512544A (en) 2016-04-28
CA2905671A1 (en) 2014-09-18
WO2014158256A1 (en) 2014-10-02
WO2014165190A2 (en) 2014-10-09
WO2014165190A3 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
EP2861227A4 (en) Omega-3 pentaenoic acid compositions and methods of use
HK1213023A1 (en) Compositions and methods of nucleic acid-targeting nucleic acids
IL245550A0 (en) Compositions and methods of using transposons
HK1211866A1 (en) Antioxidant compositions and methods of using the same
HK1214171A1 (en) Cenicriviroc compositions and methods of making and using the same
EP3735963C0 (en) Self-emulsifying composition of omega-3 fatty acid
SG10201800243XA (en) SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
IL265876A (en) Compositions comprising 15-ohepa and methods of using the same
EP2953474A4 (en) Compositions and methods
EP2964235A4 (en) Antimicrobial-antibiofilm compositions and methods of use thereof
GB201313423D0 (en) Compositions and methods
HK1221416A1 (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
GB201308072D0 (en) Compositions and methods
PL2997117T3 (en) Use of an ester
SG11201602331QA (en) Compositions and methods utilizing lysophosphatidylcholine scaffolds
GB201305813D0 (en) Compositions and methods
SG11201505891VA (en) Catalyst compositions and methods of making and using same
EP2968246A4 (en) Omega-3 pentaenoic acid compositions and methods of use
EP2964610A4 (en) Vinylsulfone-based 18f-labeling compositions and methods and uses thereof
EP2929041A4 (en) Omega-3 pentaenoic acid compositions and methods of use
IL245588A0 (en) Solid compositions of triglycerides and uses thereof
IL240734A0 (en) Methods and compositions for preparation of nucleic acids
ZA201505825B (en) Coating compositions and methods of use
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
GB201310349D0 (en) Composition and method of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/232 20060101ALI20160628BHEP

Ipc: A61K 31/202 20060101AFI20160628BHEP

Ipc: A61K 9/48 20060101ALI20160628BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170201